Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Best in class 2and 3 year data

<< Previous

Bullboard Posts

Next >>

Comment by DeathXray33on Oct 14, 2024 1:13pm

230 Views

Post# 36265332

RE:RE:Best in class 2and 3 year data

wildbird1 wrote: Thanks Enriquesuave, good post.

1) You are correct, TLT 21.4% at 3 years is huge compared to J&J Tar-200(4.7%).

2) In this link...
.Study Details | A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Gurin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | ClinicalTrials.gov
Under '' How is the study designed (Participant Group/Arm'').

It said '' Tar-200 will be dosed every 3 weeks(Q3W) for up to 24 weeks(6 months), then every 12 weeks through Week 99''.
Tar-200 is not exactly a ''One And Done Treatment'' like TLT-Ruvidar.

3) Johnson & Johnson Tar-200 is another very good exemple of a Big Pharma Company, that in spite of having a huge market cap of 388 BillionUS, J&J could not come up with a decent'' One And Done Treatment'' for BCG resistant patients.

Question?
Could it be possible, that as we speak, many of these hundred billion$ Big Pharma Company, are already talking with D.Lbiati???

enriquesuave wrote: so far we beat all competitors on 2 and 3 year data and by far. J&J tar 200 is down to 4.7% at 3 years and we are aiming for 21.4% as per Kaplan Meyer projections so far.. This shows how all other treatments show rapidly declining CR rates once they stop treating. We also beat 2 years data of recently approved combination treatment Anktiva/ BCG. 24%% vs 25.6% for us based on Kaplan Meyer projection. Can the FDA give us AA or even full approval right away?